New Jersey, USA-based biotechnology firm Quantum Genomics, which is seeking to transform the discoveries and developments of academic research into treatments for human diseases, says that it is setting up its European headquarters in Massy, close to Paris, France. The group's chief executive, Lionel Segard, will be president of the new European unit, the location of which has been selected due to its high concentration of technology activities, which will facilitate the identification and development of innovative projects in the field of human health, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze